Protocol development and clinical studies can be adapted to involve elderly patients. Acknowledgment that the drug in question will have use in the elderly, and that special chemical and physiological conditions affect the drug, must be made in the study design. Practical applications for Phase 3 studies in dementia are discussed.
TempleR: FDA Discussion Paper on Testing of Drugs in the Elderly. Department of Health and Human Services, Public Health Service, Food and Drug Administration, September 1983.
2.
Guidance notes on applications for product licenses. Medicines Act 1968. Annex 15, pp A-15–3 to A-15–12.
3.
GruenbergEM: Mental health survey of older persons, in HochPCZubinJ (eds): Comparative Epidemiology of the Mental Disorders. New York, Grune and Stratton, 1961, pp 13–23.
4.
NielsenX: Gerontopsychiatric period-prevalence investigation in a geographically delimited population. Acta Psychiatr Scand1963;38:307–339.
5.
RosenwarkeIYaffeeWSagiPC: The recent decline in mortality in the extreme aged: An analysis of statistical data. Am J Public Health1980;70: 1074–1080.
6.
ReisbergB: WHO Global Programme for Health of the Elderly. Presented at “Geriatric Drug Testing and Development-Practical Applications,”DIA Workshop, Bethesda, MD, 31 March-2 April, 1985.
7.
HachinskiVCIliffLDZilhaE: Cerebral flow in dementia. Arch Neurol1975;32:632–637.
